CSPC Pharmaceutical's (HKG:1093) CPO301 has been granted the third Fast Track designation by the US Food and Drug Administration (FDA) for lung cancer patients, a Monday Hong Kong bourse filing said.

In particular, the designation is for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

"The Fast Track designations in all subtypes of NSCLC were granted based on promising clinical efficacy data," said CSPC.